1.•

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation [Internet]. 2019 [cited 2021 Jul 28];140(11):e596–646. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000000678. Latest ACC/AHA guidelines on the primary prevention of cardiovascular disease.

2.•

Nasir K, Cainzos-Achirica M. Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ [Internet]. 2021 [cited 2021 Jul 28];373. Available from: https://www.bmj.com/content/373/bmj.n776. Comprehensive review paper on coronary artery calcium scoring in primary prevention of cardiovascular disease.

3.

DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162(4):266–75.

Article  Google Scholar 

4.

Blaha MJ, Whelton SP, Al Rifai M, Dardari ZA, Shaw LJ, Al-Mallah MH, et al. Rationale and design of the coronary artery calcium consortium: a multicenter cohort study. J Cardiovasc Comput Tomogr. 2017;11(1):54–61.

Article  Google Scholar 

5.

Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol [Internet]. 1990 [cited 2021 Jul 28];15(4):827–32. Available from: https://pubmed.ncbi.nlm.nih.gov/2407762/.

6.•

Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, et al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33–60. Updated National Lipid Association scientific statement on coronary artery calcium scoring.

Article  Google Scholar 

7.

Peters SAE, Ruijter HM den, Bots ML, Moons KGM. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart [Internet]. 2012 [cited 2021 Jul 28];98(3):177–84. Available from: https://heart.bmj.com/content/98/3/177.

8.

Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med [Internet]. 2012 [cited 2021 Jul 28];367(14):1310–20. Available from: https://pubmed.ncbi.nlm.nih.gov/23034020/.

9.

J Yeboah, R Young, RL McClelland, JC Delaney, TS Polonsky, FZ Dawood, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol [Internet]. 2016 [cited 2021 Jul 28];67(2):139–47. Available from: https://pubmed.ncbi.nlm.nih.gov/26791059/.

10.

Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA [Internet]. 2012 [cited 2021 Jul 28];308(8):788–95. Available from: https://jamanetwork.com/journals/jama/fullarticle/1352110.

11.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation [Internet]. 2014 [cited 2021 Jul 28];129(25 Suppl 2). Available from: https://pubmed.ncbi.nlm.nih.gov/24222018/.

12.

Amin NP, Martin SS, Blaha MJ, Nasir K, Blumenthal RS, Michos ED. Headed in the right direction but at risk for miscalculation: a critical appraisal of the 2013 ACC/AHA risk assessment guidelines. J Am Coll Cardiol [Internet]. 2014 [cited 2021 Jul 28];63(25 Pt A):2789–94. Available from: https://pubmed.ncbi.nlm.nih.gov/24814487/.

13.

Nasir K, Bittencourt MS, Blaha MJ, Blankstein R, Agatson AS, Rivera JJ, et al. Implications of coronary artery calcium testing among statin candidates according to American College of Cardiology/American Heart Association Cholesterol Management Guidelines MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2015;66(15):1657–68.

CAS  Article  Google Scholar 

14.

Orringer CE, Maki KC. HOPE for rational statin allocation for primary prevention: a coronary artery calcium picture is worth 1000 words. Mayo Clin Proc [Internet]. 2020 [cited 2021 Aug 5];95:1740–9. Available from: https://doi.org/10.1016/j.mayocp.2020.01.016.

15.

Shareghi S, Ahmadi N, Young E, Gopal A, Liu ST, Budoff MJ. Prognostic significance of zero coronary calcium scores on cardiac computed tomography. J Cardiovasc Comput Tomogr [Internet]. 2007 [cited 2021 Jul 28];1(3):155–9. Available from: https://pubmed.ncbi.nlm.nih.gov/19083900/.

16.

Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, et al. Interplay of coronary artery calcium and risk factors for predicting CVD/CHD mortality: the CAC consortium. JACC Cardiovasc Imaging [Internet]. 2020 [cited 2021 Jul 28];13(5):1175–86. Available from: https://pubmed.ncbi.nlm.nih.gov/31734198/.

17.

Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Cury RC, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging [Internet]. 2009 [cited 2021 Jul 28];2(6):675–88. Available from: https://pubmed.ncbi.nlm.nih.gov/19520336/.

18.

Blaha M, Budoff MJ, Shaw LJ, Khosa F, Rumberger JA, Berman D, et al. Absence of coronary artery calcification and all-cause mortality. JACC Cardiovasc Imaging [Internet]. 2009 [cited 2021 Jul 28];2(6):692–700. Available from: https://pubmed.ncbi.nlm.nih.gov/19520338/.

19.

Sandoval Y, Bielinski SJ, Daniels LB, Blaha MJ, Michos ED, DeFilippis AP, et al. Atherosclerotic cardiovascular disease risk stratification based on measurements of troponin and coronary artery calcium. J Am Coll Cardiol. 2020;76(4):357–70.

CAS  Article  Google Scholar 

20.

Blaha MJ, Nasir K, Budoff MJ, Dardari ZA, Blumenthal RS, Pollack S, et al. Impact of C-reactive protein and coronary artery calcium on benefit observed with atorvastatin. J Am Coll Cardiol [Internet]. 2018 [cited 2021 Jul 28];71(21):2487–8. Available from: http://europepmc.org/article/MED/29793637.

21.

Mahabadi AA, Möhlenkamp S, Lehmann N, Kälsch H, Dykun I, Pundt N, et al. CAC score improves coronary and CV risk assessment above statin indication by ESC and AHA/ACC primary prevention guidelines. JACC Cardiovasc Imaging [Internet]. 2017 [cited 2021 Jul 28];10(2):143–53. Available from: https://pubmed.ncbi.nlm.nih.gov/27665163/.

22.

Mitchell JD, Fergestrom N, Gage BF, Paisley R, Moon P, Novak E, et al. Impact of statins on cardiovascular outcomes following coronary artery calcium scoring. J Am Coll Cardiol [Internet]. 2018 [cited 2021 Jul 28];72(25):3233–42. Available from: https://pubmed.ncbi.nlm.nih.gov/30409567/.

23.

Nasir K. Message for 2018 cholesterol management guidelines update: time to accept the power of zero. J Am Coll Cardiol [Internet]. 2018 [cited 2021 Jul 28];72(25):3243–5. Available from: https://pubmed.ncbi.nlm.nih.gov/30409568/.

24.

Hecht H, Blaha MJ, Berman DS, Nasir K, Budoff M, Leipsic J, et al. Clinical indications for coronary artery calcium scoring in asymptomatic patients: expert consensus statement from the Society of Cardiovascular Computed Tomography. J Cardiovasc Comput Tomogr [Internet]. 2017 [cited 2021 Jul 28];11(2):157–68. Available from: https://pubmed.ncbi.nlm.nih.gov/28283309/.

25.•

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168–209. Latest AHA/ACC guidelines on management of blood cholesterol.

Article  Google Scholar 

26.•

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [Internet]. Vol. 41, European Heart Journal. Oxford University Press; 2020 [cited 2020 Jul 28]. p. 111–88. Available from: https://academic-oup-com.proxy1.library.jhu.edu/eurheartj/article/41/1/111/5556353. Latest ESC/EAS guidelines for the management of dyslipidemias.

27.

Lee SE, Chang HJ, Sung JM, Park HB, Heo R, Rizvi A, et al. Effects of statins on coronary atherosclerotic plaques: the PARADIGM study. JACC Cardiovasc Imaging. 2018;11(10):1475–84.

Article  Google Scholar 

28.

McEvoy JW, Blaha MJ, DeFilippis AP, Budoff MJ, Nasir K, Blumenthal RS, et al. Coronary artery calcium progression: an important clinical measurement? Vol. 56, Journal of the American College of Cardiology. Elsevier USA; 2010. p. 1613–22.

29.

Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229. https://doi.org/10.1186/s12916-015-0459-4.

30.

Daida H, Dohi T, Fukushima Y, Ohmura H, Miyauchi K. The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy: insights from IVUS trials. J Atheroscler Thromb [Internet]. 2019 [cited 2021 Jul 28];26(7):592–600. Available from: https://pubmed.ncbi.nlm.nih.gov/31118346/.

31.

Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol [Internet]. 2015 [cited 2021 Jul 28];65(13):1273–82. Available from: https://pubmed.ncbi.nlm.nih.gov/25835438/.

32.•

Rifai MA, Blaha MJ, Patel J, Xiaoming J, Cainzos-Achirica M, Greenland P, Budoff M, Yeboah J, Nasir K, Al-Mallah MH, Virani SS. Coronary Artery Calcification, Statin Use and Long-Term Risk of Atherosclerotic Cardiovascular Disease Events (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2020;125(6):835–9. https://doi.org/10.1016/j.amjcard.2019.12.031. Manuscript highlighting role of coronary artery calcium scoring in statin users.

33.•

Osei AD, Mirbolouk M, Berman D, Budoff MJ, Miedema MD, Rozanski A, et al. Prognostic value of coronary artery calcium score, area, and density among individuals on statin therapy vs. non-users: the coronary artery calcium consortium. Atherosclerosis [Internet]. 2021 [cited 2021 Jul 28];316:79–83. Available from: https://pubmed.ncbi.nlm.nih.gov/33121743/. Manuscript highlighting role of coronary artery calcium scoring in statin user versus non-users.

34.•

Peng AW, Mirbolouk M, Orimoloye OA, Osei AD, Dardari Z, Dzaye O, et al. Long-term all-cause and cause-specific mortality in asymptomatic patients with CAC ≥1,000: results from the CAC consortium. JACC Cardiovasc Imaging [Internet]. 2020 [cited 2021 Jul 28];13(1):83–93. Available from: https://doi.org/10.1016/j.jcmg.2019.02.005. Manuscripts highlighting that CAC ≥ 1000 is a unique high-risk phenotype.

35.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med [Internet]. 2017 [cited 2021 Jul 28];376(18):1713–22. Available from: https://pubmed.ncbi.nlm.nih.gov/28304224/

36.•

Peng AW, Dardari ZA, Blumenthal RS, Dzaye O, Obisesan OH, Uddin SMI, et al. Very high coronary artery calcium (≥1000) and association with cardiovascular disease events, non–cardiovascular disease outcomes, and mortality. Circulation [Internet]. 2021 [cited 2021 Jul 28];1571–83. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.050545. Manuscripts highlighting that CAC ≥ 1000 is a unique high-risk phenotype.

37.

Russell C, Sheth S, Jacoby D. A clinical guide to combination lipid-lowering therapy. Curr Atheroscler Reports 2018 204 [Internet]. 2018 [cited 2021 Jul 28];20(4):1–9. Available from: https://link.springer.com/article/https://doi.org/10.1007/s11883-018-0721-2.

38.

Adhyaru BB, Jacobson TA. Role of non-statins, LDL-C thresholds, and special population considerations: a look at the updated 2016 ACC Consensus Committee Recommendations. Curr Atheroscler Rep [Internet]. 2017 [cited 2021 Jul 28];19(6). Available from: https://pubmed.ncbi.nlm.nih.gov/28500517/.

39.

Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet (London, England) [Internet]. 2019 [cited 2021 Jul 28];393(10186):2155–67. Available from: https://pubmed.ncbi.nlm.nih.gov/31226053/.

40.

McNeil JJ, Woods RL, Nelson MR, Reid CM, Kirpach B, Wolfe R, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med [Internet]. 2018 [cited 2021 Jul 28];379(16):1499–508. Available from: https://pubmed.ncbi.nlm.nih.gov/30221596/.

41.

Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet (London, England) [Internet]. 2018 [cited 2021 Jul 28];392(10152):1036–46. Available from: https://pubmed.ncbi.nlm.nih.gov/30158069/.

42.

Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med [Internet]. 2018 [cited 2021 Jul 28];379(16):1529–39. Available from: https://pubmed.ncbi.nlm.nih.gov/30146931/.

43.

Miedema MD, Duprez DA, Misialek JR, Blaha MJ, Nasir K, Silverman MG, et al. Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Qual Outcomes. 2014;7(3):453–60.

Article  Google Scholar 

44.•

Cainzos-Achirica M, Greenland P. Coronary artery calcium for personalized risk management—a second chance for aspirin in primary prevention? JAMA Cardiol [Internet]. 2021 [cited 2021 Jul 28];6(2):187–8. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2772383. Manuscript emphasizing the importance of coronary artery calcium scoring for aspirin allocation.

45.

Ajufo E, Ayers CR, Vigen R, Joshi PH, Rohatgi A, de Lemos JA, et al. Value of coronary artery calcium scanning in association with the net benefit of aspirin in primary prevention of atherosclerotic cardiovascular disease. JAMA Cardiol [Internet]. 2021 [cited 2021 Jul 28];6(2):179–87. Available from: https://pubmed.ncbi.nlm.nih.gov/33112372/.

46.

Vries FM de, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients. Drugs 2012 7218 [Internet]. 2012 [cited 2021 Jul 28];72(18):2365–73. Available from: https://link.springer.com/article/10.2165/11638240-000000000-00000.

47.

Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, et al. The association of coronary artery calcification with subsequent incidence of cardiovascular disease in type 1 diabetes: the DCCT/EDIC trials. JACC Cardiovasc Imaging [Internet]. 2019 [cited 2021 Jul 28];12(7 Pt 2):1341–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30878435/.

48.

Guo J, Erqou SA, Miller RG, Edmundowicz D, Orchard TJ, Costacou T. The role of coronary artery calcification testing in incident coronary artery disease risk prediction in type 1 diabetes. Diabetologia [Internet]. 2018 [cited 2021 Jul 28];62(2):259–68. Available from: https://europepmc.org/articles/PMC6324941.

49.

Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD, DePalma SM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol [Internet]. 2016 [cited 2021 Jul 28];68(1):92–125. Available from: https://pubmed.ncbi.nlm.nih.gov/27046161/.

50.

Valenti V, Hartaigh BÓ, Cho I, Schulman-Marcus J, Gransar H, Heo R, et al. Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients. Circ Cardiovasc Imaging [Internet]. 2016 [cited 2021 Jul 28];9(2). Available from: https://pubmed.ncbi.nlm.nih.gov/26848062/.

51.

Malik S, Zhao Y, Budoff M, Nasir K, Blumenthal RS, Bertoni AG, et al. Coronary artery calcium score for long-term risk classification in individuals with type 2 diabetes and metabolic syndrome from the multi-ethnic study of atherosclerosis. JAMA Cardiol [Internet]. 2017 [cited 2021 Jul 28];2(12):1332–40. Available from: https://pubmed.ncbi.nlm.nih.gov/29117273/.

52.

Cainzos-Achirica M, Patel KV, Quispe R, Joshi PH, Khera A, Ayers C, et al. Coronary artery calcium for the allocation of GLP-1RA for primary prevention of atherosclerotic cardiovascular disease. JACC Cardiovasc Imaging. 2021.

53.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension [Internet]. 2018 [cited 2021 Jul 28];71(6):1269–324. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29133354.

54.

McEvoy JW, Martin SS, Dardari ZA, Miedema MD, Sandfort V, Yeboah J, et al. Coronary artery calcium to guide a personalized risk-based approach to initiation and intensification of antihypertensive therapy. Circulation [Internet]. 2017 [cited 2021 Jul 28];135(2):153–65. Available from: https://pubmed.ncbi.nlm.nih.gov/27881560/.

55.•

Uddin SMI, Mirbolouk M, Kianoush S, Orimoloye OA, Dardari Z, Whelton SP, et al. Role of coronary artery calcium for stratifying cardiovascular risk in adults with hypertension. Hypertens (Dallas, Tex 1979) [Internet]. 2019 May 1 [cited 2021 Jul 28];73(5):983–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30879359/. Recent manuscript that showed the unique role of CAC in stratifying risk in patients with hypertension.

56.

Zhang Y, Vittinghoff E, Pletcher MJ, Allen NB, Zeki Al Hazzouri A, Yaffe K, et al. Associations of blood pressure and cholesterol levels during young adulthood with later cardiovascular events. J Am Coll Cardiol [Internet]. 2019 [cited 2021 Jul 28];74(3):330–41. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109719352969.

57.

Gidding SS, Robinson J. It is now time to focus on risk before age 40. J Am Coll Cardiol [Internet]. 2019 [cited 2021 Jul 28];74(3):342–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0735109719352957.

58.

Carr JJ, Jacobs DR, Terry JG, Shay CM, Sidney S, Liu K, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol. 2017;2(4):391–9.

Article  Google Scholar 

59.•

Miedema MD, Dardari ZA, Nasir K, Blankstein R, Knickelbine T, Oberembt S, et al. Association of coronary artery calcium with long-term, cause-specific mortality among young adults. JAMA Netw Open [Internet]. 2019 [cited 2021 Jul 28];2(7):e197440. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2738350. Manuscripts emphasizing the importance of CAC in young adults in large cohorts.

60.•

Osei AD, Uddin SMI, Dzaye O, Achirica MC, Dardari ZA, Obisesan OH, et al. Predictors of coronary artery calcium among 20-30-year-olds: the Coronary Artery Calcium Consortium. Atherosclerosis. 2020;301:65–8. Manuscripts emphasizing the importance of CAC in young adults in large cohorts.

Article  Google Scholar 

61.

Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, et al. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc [Internet]. 2014 [cited 2021 Jul 28];89(10):1350–9. Available from: https://pubmed.ncbi.nlm.nih.gov/25236430/.

62.

MB Mortensen, V Fuster, P Muntendam, R Mehran, U Baber, S Sartori, et al. A simple disease-guided approach to personalize ACC/AHA-recommended statin allocation in elderly people: the BioImage study. J Am Coll Cardiol [Internet]. 2016 [cited 2021 Jul 28];68(9):881–91. Available from: https://pubmed.ncbi.nlm.nih.gov/27561760/.

63.

Elias-Smale SE, Proença RV, Koller MT, Kavousi M, Van Rooij FJA, Hunink MG, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56(17):1407–14.

Article  Google Scholar 

64.

Pragmatic evaluation of events and benefits of lipid-lowering in older adults—full text view—ClinicalTrials.gov [Internet]. [cited 2021 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04262206.

65.•

Mszar R, Nasir K, Santos RD. Coronary artery calcification in familial hypercholesterolemia. Circulation [Internet]. 2020 [cited 2021 Jul 28];1405–7. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.049057. Manuscripts highlighting role of CAC in familial hypercholesterolemia.

66.•

Mszar R, Grandhi GR, Valero-Elizondo J, Virani SS, Blankstein R, Blaha M, et al. Absence of coronary artery calcification in middle-aged familial hypercholesterolemia patients without atherosclerotic cardiovascular disease. JACC Cardiovasc Imaging [Internet]. 2020 [cited 2021 Jul 28];13(4):1090–2. Available from: https://doi.org/10.1016/j.jcmg.2019.10.013. Manuscripts highlighting role of CAC in familial hypercholesterolemia.

67.

Sandesara PB, Mehta A, O’Neal WT, Kelli HM, Sathiyakumar V, Martin SS, et al. Clinical significance of zero coronary artery calcium in individuals with LDL cholesterol ≥190 mg/dL: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis [Internet]. 2020 [cited 2021 Jul 28];292:224–9. Available from: https://pubmed.ncbi.nlm.nih.gov/31604582/.

68.

Miname MH, Bittencourt MS, Moraes SR, Alves RIM, Silva PRS, Jannes CE, et al. Coronary artery calcium and cardiovascular events in patients with familial hypercholesterolemia receiving standard lipid-lowering therapy. JACC Cardiovasc Imaging. 2019;12(9):1797–804.

Article  Google Scholar 

69.

Bittencourt MS, Nasir K, Santos RD, Al-Mallah MH. Very high LDL cholesterol: the power of zero passes another test. Atherosclerosis. 2020;1(292):207–8.

Article  Google Scholar 

70.

Mortensen MB, Blaha MJ, Nordestgaard BG. Eligibility and preventive potential for new evidence-based cardiovascular drugs in secondary prevention. JAMA Cardiol. 2020;5(2):209–15.

Article  Google Scholar 

71.

Bittencourt MS, Blankstein R, Nasir K. Decreasing sample size in primary prevention studies: a potential role for coronary artery calcium score. Eur J Prev Cardiol [Internet]. 2015 [cited 2021 Jul 28];22(7):931. Available from: https://pubmed.ncbi.nlm.nih.gov/25604740/.

72.•

Cainzos-Achirica M, Bittencourt MS, Osei AD, Haque W, Bhatt DL, Blumenthal RS, et al. Coronary artery calcium to improve the efficiency of randomized controlled trials in primary cardiovascular prevention. JACC Cardiovasc Imaging. 2021;14(5):1005–16. CAC is relevant in improving randomized controlled trials in primary prevention.

Article  Google Scholar 

73.

Greenland P, Michos ED, Redmond N, Fine LJ, Alexander KP, Ambrosius WT, et al. Primary prevention trial designs using coronary imaging: a National Heart, Lung, and Blood Institute workshop. JACC Cardiovasc Imaging. 2021;14(7):1454–65.

Article  Google Scholar 

74.

Effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke—full text view—ClinicalTrials.gov [Internet]. [cited 2021 Jul 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT03872401.

75.

Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, et al. Cost-effectiveness of contemporary statin use guidelines with or without coronary artery calcium assessment in African American individuals. JAMA Cardiol [Internet]. 2020 [cited 2021 Jul 28];5(8):871–80. Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2765814.

76.

Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, et al. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis. JACC Cardiovasc Imaging. 2017;10(8):938–52.

Article  Google Scholar 

77.•

Berman AN, Blankstein R. Improving access to guideline-based coronary artery calcium testing for cardiovascular disease prevention. JAMA Cardiol [Internet]. 2019 [cited 2021 Jul 28];4(10):965–6. Available from: https://pubmed.ncbi.nlm.nih.gov/31433452/.

78.•

Dzaye O, Dardari ZA, Cainzos-Achirica M, Blankstein R, Szklo M, Budoff MJ, et al. Incidence of new coronary calcification: time to conversion from CAC = 0. J Am Coll Cardiol. 2020;75(13):1610–3. Important manuscript addressing repeat CAC scanning.

Article  Google Scholar